News Article | April 24, 2014
Aastrom Biosciences, a developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, reported that it has entered into an agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks. Through this acquisition, Aastrom is acquiring commercial rights to three marketed cell therapy products. These products include Carticel, an autologous chondrocyte implant currently marketed in the US for the treatment of articular cartilage defects, Epicel, a permanent skin replacement for burns greater than or equal to 30% of total body surface area, and MACI, a third-generation ACI product currently marketed in the EU. Aastrom will also acquire manufacturing and production centers located in the US and Denmark. Sanofi acquired the CTRM business in 2011 through the acquisition of Genzyme Corporation.
Aastrom Biosciences | Date: 2010-12-07
The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.
Aastrom Biosciences | Date: 2013-09-25
Aastrom Biosciences | Date: 2011-06-10
The present invention provides methods for treating critical limb ischemia (CLI), including increasing wound healing, decreasing wound size, increasing survival-free amputation, preventing amputation, preventing or delaying de novo gangrene, increasing survival probability, and preventing or delaying death, in subjects who prevent a vascular occlusion that cannot be resolved by using a standard method of revascularization, i.e. a subject with no-option CLI. Methods of the invention include administering to a subject with no-option CLI an isolated cell composition for tissue repair comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage, wherein the viability of said cells is at least 80% and the composition contains: a) about 5-75% viable CD90
Aastrom Biosciences | Date: 2013-03-14
The present invention provides cell compositions and methods of using treating disorders, such as inflammatory disorders, such as atherosclerosis and cardiovascular disease.